DeepMed Research

Incyte

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 2.5K

Market Cap: $12.6B

Website

Introduction: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Clinical Trials

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

Phase 3

Terminated

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: Ruxolitinib

First Posted Date: 2020-05-06

Last Posted Date: 2022-01-19

Lead Sponsor: Incyte Corporation

Target Recruit Count: 211

Registration Number: NCT04377620

Locations: 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
Wenatchee Valley Hospital and Clinics, Wenatchee, Washington, United States
🇺🇸
Northshore University Health System, Chicago, Illinois, United States

and more 33 locations

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Phase 1

Active, not recruiting

Conditions: Melanoma

Interventions: Drug: INCAGN02385
Drug: INCAGN02390
Drug: INCMGA00012.

First Posted Date: 2020-05-01

Last Posted Date: 2025-04-30

Lead Sponsor: Incyte Corporation

Target Recruit Count: 61

Registration Number: NCT04370704

Locations: 🇺🇸
John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, New Jersey, United States
🇦🇺
Box Hill Hospital, Box Hill, Victoria, Australia
🇺🇸
The Angeles Clinic and Research Institute, Los Angeles, California, United States

and more 14 locations

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

Conditions: COVID-19

First Posted Date: 2020-04-21

Last Posted Date: 2021-12-15

Lead Sponsor: Incyte Corporation

Registration Number: NCT04355793

Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms

Phase 1

Recruiting

Conditions: Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome
Myelodysplastic Syndrome
Myeloproliferative Neoplasm
Relapsed or Refractory Primary Myelofibrosis
Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis)
ET (Essential Thrombocythemia)
Myelofibrosis

Interventions: Drug: INCB057643
Drug: Ruxolitinib

First Posted Date: 2020-02-21

Last Posted Date: 2025-05-22

Lead Sponsor: Incyte Corporation

Target Recruit Count: 231

Registration Number: NCT04279847

Locations: 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸
University of Miami Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
Emory University-Winship Cancer Institute, Atlanta, Georgia, United States

and more 49 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors

Phase 1

Terminated

Conditions: MSI-H/dMMR Tumors
Cutaneous Squamous Cell Carcinoma
Advanced Solid Tumors
PD-L1 Amplified Tumor (9p24.1)
Nasopharyngeal Carcinoma
Cervical Cancer
Esophageal Squamous Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma
Anal Carcinoma
DNA Polymerase Epsilon Mutated Tumors (P286R and V411L)

Interventions: Drug: INCB099318

First Posted Date: 2020-02-17

Last Posted Date: 2024-10-16

Lead Sponsor: Incyte Corporation

Target Recruit Count: 105

Registration Number: NCT04272034

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇫🇮
Turku University Hospital, Turku, Finland
🇳🇴
Haukeland University Hospital, Bergen, Norway

and more 21 locations

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors

Phase 1

Completed

Conditions: Cutaneous Squamous Cell Carcinoma
HepatoCellular Carcinoma
Mesothelioma
Advanced Solid Tumor
MSI-H/dMMR Tumors
Urothelial Carcinoma
Esophageal Squamous Cell Carcinoma
Small-cell Lung Cancer
Cervical Cancer
Merkel Cell Carcinoma

Interventions: Drug: INCB099280

First Posted Date: 2020-01-27

Last Posted Date: 2025-01-10

Lead Sponsor: Incyte Corporation

Target Recruit Count: 182

Registration Number: NCT04242199

Locations: 🇺🇸
Upmc Cancercenter, Pittsburgh, Pennsylvania, United States
🇦🇺
Chris Obrien Lifehouse, Camperdown, New South Wales, Australia
🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States

and more 18 locations

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Metastatic Squamous Non-Small Cell Lung Cancer
Metastatic Nonsquamous Non-Small Cell Lung Cancer

Interventions: Drug: Retifanlimab
Drug: Placebo
Drug: Pemetrexed
Drug: Cisplatin
Drug: Paclitaxel
Drug: Carboplatin
Drug: nab-Paclitaxel

First Posted Date: 2019-12-19

Last Posted Date: 2025-05-13

Lead Sponsor: Incyte Corporation

Target Recruit Count: 583

Registration Number: NCT04205812

Locations: 🇹🇷
Trakya Universitesi Tip Fakultesi, Edirne, Turkey
🇿🇦
Wits Clinical Research, Johannesburg, South Africa
🇺🇦
Kherson Regional Oncologic Dispensary, Kherson, Ukraine

and more 135 locations

INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)

Phase 3

Withdrawn

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Retifanlimab
Drug: Placebo
Drug: Pemetrexed
Drug: Cisplatin
Drug: Carboplatin
Drug: Paclitaxel
Drug: Etoposide
Radiation: Radiotherapy

First Posted Date: 2019-12-18

Last Posted Date: 2020-06-09

Lead Sponsor: Incyte Corporation

Registration Number: NCT04203511

A Study of Itacitinib for the Prevention of Cytokine Release Syndrome Induced by Immune Effector Cell Therapy

Phase 2

Completed

Conditions: Cytokine Release Syndrome

Interventions: Drug: Itacitinib
Drug: Immune effector cell therapy
Drug: Placebo
Biological: Yescarta

First Posted Date: 2019-08-28

Last Posted Date: 2024-03-26

Lead Sponsor: Incyte Corporation

Target Recruit Count: 112

Registration Number: NCT04071366

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Medical College of Wisconsin, Milwaukee, Wisconsin, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

Phase 3

Completed

Conditions: Non-segmental Vitiligo

Interventions: Drug: Ruxolitinib cream
Drug: Vehicle

First Posted Date: 2019-08-15

Last Posted Date: 2022-09-21

Lead Sponsor: Incyte Corporation

Target Recruit Count: 344

Registration Number: NCT04057573

Locations: 🇺🇸
Uci Beckman Laser Institute and Medical Clinic, Irvine, California, United States
🇺🇸
UCI Health Beckman Laser Institute and Medical Center, Irvine, California, United States
🇺🇸
Vitiligo & Pigmentation Institute of Southern California, Los Angeles, California, United States

and more 69 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy